{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:02:00Z","timestamp":1789682520730,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","award":["ynts202006"],"award-info":[{"award-number":["ynts202006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04725-7","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T18:14:30Z","timestamp":1773425670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-omics integration reveals tumor and microenvironmental heterogeneity in malignant pleural mesothelioma"],"prefix":"10.1007","volume":"17","author":[{"given":"Hai","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"4725_CR1","doi-asserted-by":"crossref","unstructured":"Jain M, Crites MK, Rich P, Bajantri B. Malignant pleural mesothelioma: a comprehensive review. J Clin Med. 2024;13.","DOI":"10.3390\/jcm13195837"},{"key":"4725_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-025-00640-3","volume":"11","author":"DA Fennell","year":"2025","unstructured":"Fennell DA, Sekido Y, Baas P, Husain AN, Curioni-Fontecedro A, Lim E, et al. Pleural mesothelioma. Nat Rev Dis Primers. 2025;11:56.","journal-title":"Nat Rev Dis Primers"},{"key":"4725_CR3","doi-asserted-by":"crossref","unstructured":"Holzknecht A, Illini O, Hochmair MJ, Krenbek D, Setinek U, Huemer F et al. Multimodal treatment of malignant pleural mesothelioma: real-world experience with 112 patients. Cancers (Basel). 2022;14.","DOI":"10.3390\/cancers14092245"},{"key":"4725_CR4","doi-asserted-by":"publisher","first-page":"102815","DOI":"10.1016\/j.critrevonc.2019.102815","volume":"144","author":"M Cinausero","year":"2019","unstructured":"Cinausero M, Rihawi K, Cortiula F, Follador A, Fasola G, Ardizzoni A. Emerging therapies in malignant pleural mesothelioma. Crit Rev Oncol Hematol. 2019;144:102815.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4725_CR5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun. 2019;10:1333.","journal-title":"Nat Commun"},{"key":"4725_CR6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","volume":"55","author":"L Mangiante","year":"2023","unstructured":"Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, et al. Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. Nat Genet. 2023;55:607\u201318.","journal-title":"Nat Genet"},{"key":"4725_CR7","doi-asserted-by":"publisher","first-page":"995651","DOI":"10.3389\/fonc.2022.995651","volume":"12","author":"K Yang","year":"2022","unstructured":"Yang K, Yang T, Yang T, Yuan Y, Li F. Unraveling tumor microenvironment heterogeneity in malignant pleural mesothelioma identifies biologically distinct immune subtypes enabling prognosis determination. Front Oncol. 2022;12:995651.","journal-title":"Front Oncol"},{"key":"4725_CR8","doi-asserted-by":"crossref","unstructured":"Alay A, Cordero D, Hijazo-Pechero S, Aliagas E, Lopez-Doriga A, Marin R et al. Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification. J Immunother Cancer. 2021;9.","DOI":"10.1136\/jitc-2020-001601"},{"key":"4725_CR9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s12672-025-03080-3","volume":"16","author":"L Zhao","year":"2025","unstructured":"Zhao L, Huang Y, Li J, Xie R, Li K. Integrating bulk and single-cell RNA sequencing reveals intratumor heterogeneity phenotypes and immune infiltration in pancreatic cancer. Discov Oncol. 2025;16:1325.","journal-title":"Discov Oncol"},{"key":"4725_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-023-01494-6","volume":"16","author":"D Huang","year":"2023","unstructured":"Huang D, Ma N, Li X, Gou Y, Duan Y, Liu B, et al. Advances in single-cell RNA sequencing and its applications in cancer research. J Hematol Oncol. 2023;16:98.","journal-title":"J Hematol Oncol"},{"key":"4725_CR11","doi-asserted-by":"publisher","first-page":"108679","DOI":"10.1016\/j.lungcan.2025.108679","volume":"207","author":"A Alay","year":"2025","unstructured":"Alay A, Marin R, Aliagas E, Gausachs M, Ruiz-Gil M, Macia I, et al. Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma. Lung Cancer. 2025;207:108679.","journal-title":"Lung Cancer"},{"key":"4725_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/path.5551","volume":"253","author":"A De Rienzo","year":"2021","unstructured":"De Rienzo A, Chirieac LR, Hung YP, Severson DT, Freyaldenhoven S, Gustafson CE, et al. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma. J Pathol. 2021;253:68\u201379.","journal-title":"J Pathol"},{"key":"4725_CR13","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, et al. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018;8:1548\u201365.","journal-title":"Cancer Discov"},{"key":"4725_CR14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43:668\u201372.","journal-title":"Nat Genet"},{"key":"4725_CR15","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1158\/2159-8290.CD-23-0017","volume":"14","author":"B Giotti","year":"2024","unstructured":"Giotti B, Dolasia K, Zhao W, Cai P, Sweeney R, Merritt E, et al. Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma. Cancer Discov. 2024;14:2262\u201378.","journal-title":"Cancer Discov"},{"key":"4725_CR16","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1158\/1078-0432.CCR-17-1345","volume":"24","author":"LM Schunselaar","year":"2018","unstructured":"Schunselaar LM, Quispel-Janssen J, Kim Y, Alifrangis C, Zwart W, Baas P, et al. Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses. Clin Cancer Res. 2018;24:1761\u201370.","journal-title":"Clin Cancer Res"},{"key":"4725_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","volume":"48","author":"N Alcala","year":"2019","unstructured":"Alcala N, Mangiante L, Le-Stang N, Gustafson CE, Boyault S, Damiola F, et al. Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. EBioMedicine. 2019;48:191\u2013202.","journal-title":"EBioMedicine"},{"key":"4725_CR18","doi-asserted-by":"publisher","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","volume":"4","author":"H Ujiie","year":"2015","unstructured":"Ujiie H, Kadota K, Nitadori JI, Aerts JG, Woo KM, Sima CS, et al. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers. Oncoimmunology. 2015;4:e1009285.","journal-title":"Oncoimmunology"},{"key":"4725_CR19","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/cjp2.218","volume":"7","author":"H Ollila","year":"2021","unstructured":"Ollila H, Paajanen J, Wolff H, Ilonen I, Sutinen E, Valimaki K, et al. High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma. J Pathol Clin Res. 2021;7:482\u201394.","journal-title":"J Pathol Clin Res"},{"key":"4725_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.7150\/thno.61209","volume":"12","author":"H Yang","year":"2022","unstructured":"Yang H, Berezowska S, Dorn P, Zens P, Chen P, Peng RW, et al. Tumor-infiltrating lymphocytes are functionally inactivated by CD90\u2009+\u2009stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma. Theranostics. 2022;12:167\u201385.","journal-title":"Theranostics"},{"key":"4725_CR21","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11:5120.","journal-title":"Nat Commun"},{"key":"4725_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13046-022-02582-0","volume":"42","author":"A Ries","year":"2023","unstructured":"Ries A, Flehberger D, Slany A, Pirker C, Mader JC, Mohr T, et al. Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met\/PI3K and WNT signaling but do not protect against cisplatin. J Exp Clin Cancer Res. 2023;42:27.","journal-title":"J Exp Clin Cancer Res"},{"key":"4725_CR23","doi-asserted-by":"crossref","unstructured":"Bonelli M, Terenziani R, Zoppi S, Fumarola C, La Monica S, Cretella D et al. Dual inhibition of CDK4\/6 and PI3K\/AKT\/mTOR signaling impairs energy metabolism in MPM cancer cells. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21145165"},{"key":"4725_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00280-019-03878-3","volume":"84","author":"V Galani","year":"2019","unstructured":"Galani V, Varouktsi A, Papadatos SS, Mitselou A, Sainis I, Constantopoulos S, et al. The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment. Cancer Chemother Pharmacol. 2019;84:241\u201353.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4725_CR25","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/1750743X.2025.2549240","volume":"17","author":"G Mazzaschi","year":"2025","unstructured":"Mazzaschi G, Rosati R, D\u2019Agnelli S, Minari R, Trentini F, Tamarozzi P, et al. Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy. Immunotherapy. 2025;17:879\u201390.","journal-title":"Immunotherapy"},{"key":"4725_CR26","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-22-0886","volume":"13","author":"FX Danlos","year":"2023","unstructured":"Danlos FX, Texier M, Job B, Mouraud S, Cassard L, Baldini C, et al. Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1\u2009+\u2009Antiangiogenesis in Malignant Pleural Mesothelioma. Cancer Discov. 2023;13:858\u201379.","journal-title":"Cancer Discov"},{"key":"4725_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","volume":"10","author":"SH Ou","year":"2015","unstructured":"Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, et al. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015;10:387\u201391.","journal-title":"J Thorac Oncol"},{"key":"4725_CR28","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1158\/1078-0432.CCR-19-3573","volume":"26","author":"C Pirker","year":"2020","unstructured":"Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, et al. Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup. Clin Cancer Res. 2020;26:3819\u201330.","journal-title":"Clin Cancer Res"},{"key":"4725_CR29","doi-asserted-by":"crossref","unstructured":"Severson DT, Freyaldenhoven S, Wadowski B, Hung YP, Hughes T, Yeap BY et al. Multiomic, histologic, and scRNA-seq profiling of pleural mesothelioma reveals negative prognosis associated with a novel uncommitted molecular phenotype. J Thorac Oncol. 2025.","DOI":"10.1016\/j.jtho.2025.11.019"},{"key":"4725_CR30","doi-asserted-by":"publisher","first-page":"1104560","DOI":"10.3389\/fimmu.2023.1104560","volume":"14","author":"Z Liu","year":"2023","unstructured":"Liu Z, Wan R, Bai H, Wang J. Damage-associated molecular patterns and sensing receptors based molecular subtypes in malignant pleural mesothelioma and implications for immunotherapy. Front Immunol. 2023;14:1104560.","journal-title":"Front Immunol"},{"key":"4725_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1471-2105-11-367","volume":"11","author":"R Gaujoux","year":"2010","unstructured":"Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics. 2010;11:367.","journal-title":"BMC Bioinformatics"},{"key":"4725_CR32","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"4725_CR33","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov (Camb). 2021;2:100141.","journal-title":"Innov (Camb)"},{"key":"4725_CR34","doi-asserted-by":"crossref","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573\u201387. e3529.","DOI":"10.1016\/j.cell.2021.04.048"},{"key":"4725_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-1-0716-0301-7_7","volume":"2117","author":"CB Steen","year":"2020","unstructured":"Steen CB, Liu CL, Alizadeh AA, Newman AM. Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx. Methods Mol Biol. 2020;2117:135\u201357.","journal-title":"Methods Mol Biol"},{"key":"4725_CR36","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","volume":"20","author":"S Jin","year":"2025","unstructured":"Jin S, Plikus MV, Nie Q. CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics. Nat Protoc. 2025;20:180\u2013219.","journal-title":"Nat Protoc"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04725-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04725-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04725-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:54:51Z","timestamp":1776815691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04725-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4725"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04725-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"616"}}